ObjectiveTo identify risk factors for major adverse cardiovascular events (MACE) in patients with multiple myeloma (MM) and to evaluate the performance of an external risk-score–based stratification.
The BC_cardiotox database is a result of the collaboration between the University of A Coruña and the University Hospital of A Coruña. It contains information about 531 breast cancer patients and aims
Background: Carfilzomib improves the prognosis of multiple myeloma (MM) patients but significantly increases cardiovascular toxicity. The timing and effect of Carfilzomib therapy on the left ventricul
Background and purpose: Sunitinib, a multi-targeted tyrosine kinase inhibitor, has anticancer function but it’s clinical use is often limited by cardiovascular complications. Baicalin is a flavonoid e
